Susquehanna International Group, LLP Biomea Fusion, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.23 - $10.1 $142,128 - $339,360	33,600 Added 7.18%	501,800 $5.07 Million
Q2 2024 Aug 15, 2024	SELL	$4.14 - $15.3 $234,737 - $867,510	-56,700 Reduced 10.8%	468,200 $2.11 Million
Q1 2024 May 07, 2024	SELL	$13.92 - $19.5 $2.39 Million - $3.35 Million	-171,700 Reduced 24.65%	524,900 $7.85 Million
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $5.66 Million - $13.4 Million	676,800 Added 3418.18%	696,600 $10.1 Million
Q3 2023 Nov 14, 2023	SELL	$13.44 - $23.02 $1.88 Million - $3.22 Million	-139,900 Reduced 87.6%	19,800 $272,000
Q2 2023 Aug 11, 2023	BUY	$21.66 - $41.8 $1.13 Million - $2.18 Million	52,200 Added 48.56%	159,700 $3.51 Million
Q1 2023 May 16, 2023	BUY	$6.8 - $32.35 $731,000 - $3.48 Million	107,500 New	107,500 $3.33 Million

104

17.8M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $117M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.